Arcturus Therapeutics is trading 9.57% down at $13.33 amid broader risk-off conditions.
- The S&P 500 is down 0.56% and the Nasdaq Composite is down 0.79% as investors digest elevated August producer-price inflation and firm Treasury yields.
- No new company-specific announcement directly explains the sharper decline.
- Arcturus is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference on September 10; investors await Phase II OTC-deficiency data later this month.